Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma.

Authors:
  • HAH. Avet-Loiseau
    H. Avet-Loiseau
  • PMP. Moreau
    P. Moreau
  • CMC. Mathiot
    C. Mathiot
  • CCC. Charbonnel
    C. Charbonnel
  • TFT. Facon
    T. Facon
  • MAM. Attal
    M. Attal
  • CHC. Hulin
    C. Hulin
  • GMG. Marit
    G. Marit
  • SMS. Minvielle
    S. Minvielle
  • JHJ. Harousseau
    J. Harousseau
  • IMIntergroupe Francophone du Myãlome
    Intergroupe Francophone du Myãlome

Abstract
8113 Background: Translocation t(4;14)(p16;q32) has been associated with a poor outcome in multiple myeloma. This poor prognosis has been identified both in patients treated with melphalan-prednisone (MP) and in those treated with high-dose melphalan after a VAD induction. For instance, in 100 patients with t(4;14) treated with VAD and MEL200, the median PFS and OS were 21 months and 41 months, respectively, as compared to 37 months and 65 months for patients lacking the t(4;14) (Moreau et al., Leukemia 2007). Some preliminary studies have suggested that bortezomib was able to overcome the poor prognosis of the translocation in elderly patients treated with MP-bortezomib (San Miguel et al., NEJM 2008). Methods: In order to address this important question, we analyzed 507 patients treated in the IFM, according to the IFM-2005-01 trial, arm B: induction with 4 cycles of bortezomib (Velcade)/dexamethasone (VD), followed by one or two courses of high-dose melphalan (MEL200). Results: A translocation t(4;14) w...